Safety and tolerability Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation, abdominal pain) were the primary reasons for discontinuation, especially during rapid dose escalation
These include chest pain or tightness, severe headaches, palpitations or irregular heartbeat, difficulty breathing, severe dizziness or fainting, or sudden vision changes
The mechanism behind these lipid changes is not fully understood but may relate to: Weight loss associated with GLP-1 receptor agonist therapy, which can independently improve lipid profiles Improved insulin sensitivity and glucose metabolism Possible effects on hepatic lipid metabolism, though this remains hypothetical and an area of ongoing research It is important to emphasise that any lipid-lowering effects observed with Rybelsus are secondary benefits rather than the primary therapeutic goal
Epub 2013 Jan 15
Table of Contents: What is body contouring
TikTok Shop storefront Buckeye Amino Research sells vials of Reta (Retatrutide, a GLP-1 weight loss drug developed by Eli Lilly) for Research Use Only. Buckeye Amino Research is registered as Buckeye Scents LLC, which doubles as a Scentsy business